DR Arunish Chawla,Secretary of the Department of Pharmaceticals (DoP)
Pharma Utility Bureau
Dr. Arunish Chawla, Secretary of the Department of Pharmaceuticals (DoP), has unveiled an intricate and ambitious framework poised to propel India’s pharmaceuticaland medtech industries to unprecedented heights. Underlining a multifaceted approach, Chawla articulates a commitment to excellence, innovation, and collaborative global leadership.
Charting a Course for Industry Advancement:
Within the expansive canvas of support for the pharmaceutical sector, Dr. Chawla elaborates on the nuanced strategies deployed by the DoP. From meticulously crafted schematic interventions to the far-reaching implications of non-schematic initiatives, such as the groundbreaking Production-Linked Incentive (PLI) scheme for Active Pharmaceutical Ingredients (API) and medical devices, the government demonstrates an unequivocal commitment to nurturing industry growth.
Architecting a Strategic Policy Landscape:
Dr. Chawla delves into the intricacies of a comprehensive policy framework designed to intricately map the value chains within the drug, pharma, and medtech domains. This visionary initiative aims not only to identify the critical components of finished products and starting materials but also to create a balanced tariff and GST spectrum. The ultimate goal is to incentivize value addition while meticulously avoiding duty or tax inversion along the entire value chain.
Revolutionizing Schemes and Bridging the Skill Divide:
Navigating the complex landscape of industry reform, the DoP, under Dr. Chawla’s guidance, is set to revolutionize existing schemes. By engaging with industry stakeholders through a lens of public goods, positive and negative externalities, and external economies of scale, the department aims to redress the shortage of medtech professionals. Dr. Chawla underscores the pivotal role of skilled technicians in driving innovation and progress.
A Global Paradigm Shift with Quality as the Vanguard:
Shifting its gaze from the erstwhile “China plus one” paradigm, India, guided by Dr. Chawla’s vision, is repositioning itself as “India plus” on the global stage. The DoP is actively steering efforts to supply quality medicines to countries worldwide, with a laser focus on meeting and exceeding international standards. Collaborative endeavors with global regulatory stalwarts like the USFDA and EU underscore India’s unwavering commitment to quality assurance.
Navigating the Technological Frontiers with Foresight:
Acknowledging the swift ascent of the medtech sector, Dr. Chawla paints a vivid picture of a transformative era propelled by cutting-edge technologies. From the revolutionary impact of Artificial Intelligence (AI) to the precision offered by genomics and smart medicines, the sector is poised to redefine healthcare practices on a global scale.
Diplomacy in Action: Mutual Recognition and Sovereignty Respect:
In navigating the intricate global tapestry, Dr. Chawla places significant emphasis on the imperative of mutual recognition, positioning it as a mandatory requirement. This diplomatic approach, rooted in respect for the sovereignty of export partners, reflects India’s commitment to harmonious collaboration while safeguarding its own interests.
Redrawing Schemes for Unprecedented Industry Strengthening:
As the industry’s heartbeat evolves, Dr. Chawla articulates the ongoing efforts to redraw schemes and strategically redesign industry strategies. This forward-looking approach ensures that non-tariff barriers are not merely addressed but strategically overcome, laying the foundation for sustained and holistic industry growth.
Dr. Arunish Chawla’s visionary leadership and the DoP’s initiatives set the stage for a transformative era in India’s pharmaceutical and medtech domains. With innovation, quality, and collaborative global leadership at the forefront, India is poised to emerge not just as a player but as a trailblazer in these pivotal industries.